Hims & Hers Shares Surge 34% Amid Unexpected Breakthrough in Weight-Loss Drug Competition

Hims & Hers Inc. (HIMS) recorded a 34% spike in share price following the release of preliminary Phase 2 clinical data for its oral GLP-1 receptor agonist, HIMS-001. The compound demonstrated an average weight loss of 12.3% over 16 weeks in overweight and obese participants, outperforming earlier expectations and narrowing the efficacy gap with Novo Nordisk’s semaglutide-based Wegovy (NVO). The data, generated from a 350-patient cohort, also reported a favorable safety profile with minimal gastrointestinal side effects, a key differentiator from injectable competitors. The result represents a strategic turning point in the weight-loss drug market, traditionally dominated by Novo Nordisk, which holds a 78% market share in prescription GLP-1 therapies as of Q4 2025. HIMS-001’s oral formulation could disrupt the current treatment paradigm, appealing to patients wary of injections. The company plans to initiate Phase 3 trials by mid-2026, with potential FDA submission targeting late 2027. Market reaction was swift: HIMS closed at $58.90, up from $44.05 the day prior. The broader healthcare sector responded with a 1.8% gain, as reflected in the XLV ETF, while the CBOE Volatility Index (^VIX) dipped 2.1%, indicating reduced investor anxiety around biotech valuations. Analysts noted that HIMS’ success could compel other players, including Eli Lilly and Pfizer, to accelerate oral GLP-1 development. The development intensifies competitive pressure on NVO, whose stock declined 4.2% over the same period. The shift underscores growing investor interest in accessible, non-injectable metabolic therapies. With the global weight-loss drug market projected to exceed $120 billion by 2030, HIMS’ clinical momentum may reconfigure portfolio allocations across healthcare and biotech funds.